Barclays
MCRB icon

Barclays’s Seres Therapeutics MCRB Stock Holding History

Barclays’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-840
Closed -$269K – 7028
2017
Q3 		$269K Buy
+840
New +$230K ﹤0.01% 4171

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Barclays's MCRB Position: Q2 2026 in Review

Barclays reduced its Seres Therapeutics (MCRB) stake by 97% in Q2 2026, selling an estimated $48.3K and leaving 167 shares worth $1.32K. The position accounts for ﹤0.01% of the portfolio, ranked #4906.

Barclays first reported a position in MCRB in Q4 2015 and has held it in 42 quarters since. The position peaked at $2.18M in Q4 2021. 36 funds tracked by Wall St. Rank hold MCRB as of Q2 2026.

  • Barclays held 167 shares of Seres Therapeutics worth $1.32K as of Q2 2026.
  • Barclays sold 6,340 Seres Therapeutics shares in Q2 2026, an estimated $48.3K.
  • Seres Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4906 holding.
  • Barclays first reported a position in Seres Therapeutics in Q4 2015 and has held it in 42 quarters since.
  • Barclays's Seres Therapeutics position peaked at $2.18M in Q4 2021.
  • 36 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.